logo
Having friends can help you live longer. Here's how to find them

Having friends can help you live longer. Here's how to find them

CTV News2 days ago
After working from home all day, your takeout order arrives and you start binge-watching your favourite show alone. Sounds ideal, right? Except doing this routinely could shorten your life.
And that's not because of the nutritional content of your dinner. It's because having strong, positive relationships is one of the best ways to extend your life, according to research.
'Human beings just are a fundamentally social species. We have a fundamental need to belong,' said Dr. Amit Kumar, associate professor of marketing and psychology at the University of Texas at Austin's McCombs School of Business.
With everything else you have going on, why should you make a change? Because the cost of loneliness is huge.
'The mortality impact of being socially disconnected is similar to that caused by smoking up to 15 cigarettes a day, and even greater than that associated with obesity and physical inactivity,' wrote then US Surgeon General Dr. Vivek H. Murthy in his 2023 advisory on the 'healing effects' of social connection .
The lack of strong social ties has been linked to a greater risk of problems with health or well-being, including more stress, high blood pressure, premature death and poor coping skills.
But finding friends as an adult can be hard. Some people's mindsets hinder their ability to make connections, while a lack of affordable places to meet is a challenge for others, said Danielle Bayard Jackson, director of the Women's Relational Health Institute.
But the effort is worth it. Here's how Jackson and other experts suggest you combat those limitations and find your community.
Breaking down barriers to friendship
If you want to make more connections in your life, consider how you might be counteracting that goal and prepare to change, said Jackson, author of 'Fighting for Our Friendships: The Science and Art of Conflict and Connection in Women's Relationships.'
Many people have a fear of rejection, real or perceived, while others have social anxiety, Jackson said. But if you never take risks, Kumar noted, you never give your brain a chance to see that you actually can socialize.
Practicing cognitive behavioural therapy or setting yourself up for 'micro' moments to put yourself out there can help you regulate social anxiety and rejection-sensitivity, experts said.
Not everyone is going to like you, and you need to learn to regulate your emotional response to that. That could look like noting the sting and thinking, 'Well, that was awkward' — but not immediately labelling that person a jerk or deciding something about you is defective.
'Some psychologists call it exposure therapy,' Jackson said. 'I've seen them assign a client the task of going and asking for crazy things and intentionally trying to go and collect nos.'
Engage with a waiter a bit longer than normal and ask for a menu accommodation you know they will decline, Jackson said. Check out at the grocery store with a cashier instead of self-checkout to practice your social skills.
If time is an issue, think about canceling some commitments so you can prioritize your social life, experts said. But you should also change what you consider acceptable hangouts — setting time limits is OK, especially when the alternative is not seeing anyone at all.
Dr. Lauren Cook, a clinical psychologist, suggests doing mundane activities with friends more often instead of always having bigger, less frequent events focused on catching up.
If you want to see someone but also need to run errands, hit the gym or fold laundry, ask them to join you. Instead of drinks on a Friday, plan a short Tuesday game night and ask your guests to eat dinner beforehand so you only have to provide a snack.
Defy environmental challenges to socializing
Some people cite the 'collapse of third places' as a hindrance to making friends, Jackson said. That's true, she added, but those places are closing in part because of low attendance.
Today's culture of convenience is also to blame, Jackson and Cook said — think grocery delivery orders, mobile order counters, digital reading devices or livestreamed religious services. These have many perks, especially for people with mobility issues, 'but I cannot help but to think about the cost,' Jackson said.
'We tend to romanticize those serendipitous moments of, like, you're in a coffee shop and you start chatting with the girl in front of you and you guys hit it off,' Jackson said.
But that can't happen if we're acting like 'little night cooters,' Cook said — quickly hopping out, getting our food and then going back to our caves. When clients seek Jackson's help with finding friends, they list all their delivery subscriptions and other conveniences — such as frequent mobile orders — and then eliminate some, which lead to those serendipitous moments.
Don't think in black or white, Jackson said. 'If you see it as zero friends or go out and make besties, that's a lot,' she added. But if you see all that's available to you — like the neighbor or moviegoer you always run into — you can see what happens.
Finally, get off your phone. When you're always zoned in on your screen, you appear standoffish and won't notice people you might like.
Go out to meet likeminded people
To determine where to meet people, consider your values and your ideal friend, Jackson said. If you love helping people, look for volunteering opportunities. If your ideal friend reads books, where would she be on a Wednesday night? Probably at a book club meeting or a bookstore, so go to one.
Frequent local libraries, farmers markets and parks. Look online for interest clubs or events, or try an app for finding friends nearby. Take a class on something you have always wanted to do, such as learning a specific dance style or cooking a special cuisine.
Maybe even reach out to an old friend you have lost touch with, said psychologist Dr. Marisa G. Franco, an associate fellow at the University of Maryland honors program and author of 'Platonic: How the Science of Attachment Can Help You Make — and Keep — Friends.' We often underestimate how happy people will be to hear from us, she noted.
When Cook became a new mom, she brought her baby along on her walks and made many friends by asking other women about their babies and talking about her own. Cook also suggested wearing something that could be a conversation starter, such as a T-shirt featuring your favorite artist.
And don't forget you can be a leader, Cook said. 'A lot of people are hoping these opportunities will just fall in their lap. If you're not finding it, build it.'
Cook recalled when her friends hosted dinners they called 'friends of friends.' They would invite a friend who also had to bring someone. 'That completely built out their whole social world because their friends were all getting to know each other,' Cook said. 'It became this popular thing where there was a wait list.'
Another person couldn't find a quilting club for millennials, so they started a monthly class in a rented space, Cook said.
That do-it-yourself spirit is what sparked some of the platforms that matchmake strangers for restaurant dinners or provide spaces for people to start something themselves. Those initiatives include The Lonely Girls Club in the United Kingdom; California's Groundfloor, an 'after-school club' for millennials; RealRoots in the United States; and the global-based Time Left.
How to talk to strangers
Small talk may seem annoying, but it's necessary, said Cook, who also wrote 'Generation Anxiety: A Millennial and Gen Z Guide to Staying Afloat in an Uncertain World.' Deep relationships take time to build.
If you find yourself running out of topics, Cook recommends asking questions about their favorite things that are relevant to the situation — if you're at a jazz bar, for example, ask someone about their favorite jazz artists.
If your platonic interest loves hiking, say you'll send them links to a couple of good spots if they give you their number or Instagram, Jackson suggested. Later that night, send them the links. After a week, ask if they went and keep talking.
Cook also suggests using the 'listen and link' technique. As you're listening to someone, think about what you can link to the conversation, use that and build from there. If someone's talking about their trip to Costa Rica and you love monkeys, ask what kinds of monkeys they saw in Costa Rica.
One of my favourite ways to keep a conversation going with someone new? Staying curious. When someone is totally new to you, there is a whole decades-long world of information to learn about them. When you're aware of that, how could you ever have nothing to talk about? Cook agrees.
How to keep a friend
Although many people know romantic partnerships require consistent effort and nurturing, many think friendship should be the opposite: easy, natural and organic, Jackson said. This idea may be because growing up, we made friends more easily because we had classes or sports practice with them every day.
But in adulthood, that idea is a falsehood that leads to fizzled-out friendships and loneliness, Jackson said.
Maintaining friendships takes a lot of intention, experts said. Set reminders to check in, be a good listener, don't be judgmental and remember what your new acquaintances like so you can suggest meaningful ways to spend time together — and maybe even live longer.
By Kristen Rogers, CNN
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Top FDA official restricted COVID vaccine approvals against advice of agency staff
Top FDA official restricted COVID vaccine approvals against advice of agency staff

Globe and Mail

time6 hours ago

  • Globe and Mail

Top FDA official restricted COVID vaccine approvals against advice of agency staff

The government's top vaccine official working under Health Secretary Robert F. Kennedy Jr. recently restricted the approval of two COVID-19 vaccines, disregarding recommendations from government scientists, according to federal documents released Wednesday. The new memos from the Food and Drug Administration show how the agency's vaccine chief, Dr. Vinay Prasad, personally intervened to place restrictions on COVID shots from vaccine makers Novavax and Moderna. Both vaccines were approved by the FDA in May after months of analysis by rank-and-file FDA reviewers. But internal correspondence show Prasad disagreed with staffers who planned to approve the shots for everyone 12 and older, similar to previous COVID vaccines. The scientists had concluded the benefit from the vaccines and the risk of COVID-19 outweighed the risk of possible side effects, which are rare. Instead Prasad decided the shots should be limited to those who face special risks from the virus — seniors or children and adults with underlying medical issues. Prasad explained that the COVID vaccine benefits must be reconsidered in light of falling rates of death and hospitalization and the possibility for vaccine side effects. It's the latest in a series of vaccine restrictions imposed by officials working under Kennedy, who has long questioned the benefits of vaccines. 'Even rare vaccination related harms both known and unknown now have higher chance of outweighing potential benefits' Prasad wrote in a five-page memo explaining his decision. COVID-19 remains a public health threat, resulting in 32,000 to 51,000 U.S. deaths and more than 250,000 hospitalizations since last fall, according to the Centers for Disease Control and Prevention. Most at risk for hospitalization are seniors and children under 2 — especially infants under 6 months. Top FDA leaders are typically not involved in the review of individual products. Officials like Prasad can overrule staffers, but such cases are rare and often controversial. News of the FDA documents was first reported by the New York Times. Prasad was hired to lead the FDA's vaccine center in May, after the previous director, Dr. Peter Marks, was forced to resign over disagreements with Kennedy. An academic researcher specializing in cancer therapies, Prasad came to prominence during the pandemic for criticizing public health measures, including the FDA's approval of COVID boosters for healthy adults and children. Since arriving at the agency he has worked with FDA Commissioner Mark Makary on new guidelines that will limit approvals of future COVID boosters to higher-risk Americans, mainly seniors and those with medical conditions like asthma and obesity. Those limits match the terms FDA recently approved for Novavax's shot, Nuvaxovid and Moderna's mNexspike. Novavax's vaccine is the only protein-based coronavirus vaccine available in the U.S. Moderna's vaccine is an updated, lower-dose version of its existing mRNA-based vaccine. The review team for the Novavax vaccine pointed to data from a study in 30,000 adults, concluding that 'the risk-benefit assessment for this vaccine technology remains favorable.' FDA staff reached a similar conclusion for the Moderna vaccine, deeming it similar in safety and effectiveness to the company's original shot. Science under siege: The rise of the wellness-conspiracy-prosperity gospel Last week, the FDA finalized new warning labeling about the risk of myocarditis, a rare form of heart inflammation, on shots from Moderna and Pfizer, the other maker of an mRNA-based shot for COVID. In his 'override memo,' reversing FDA staff's decision on the Moderna shot, Prasad pointed to the ongoing risk of myocarditis and questions about its frequency. The agency ordered Moderna to conduct further studies of the risk as a condition for the approving its updated shot. A spokesman for the administration said Prasad 'has raised serious concerns' about the issue. 'We will not ignore these risks and will ensure that the gold standard of science is used for any decisions,' said Andrew Nixon, in an emailed statement. Outside researchers have noted that cases of the heart condition tend to resolve quickly and are less severe than those associated with COVID infection itself, which can also cause myocarditis.

Hepatitis D Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment
Hepatitis D Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment

Globe and Mail

time8 hours ago

  • Globe and Mail

Hepatitis D Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment

DelveInsight's, ' Hepatitis D Pipeline Insight, 2025 ' report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Hepatitis D pipeline landscape. It covers the Hepatitis D pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatitis D pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Hepatitis D Pipeline. Dive into DelveInsight's comprehensive report today! @ Hepatitis D Pipeline Outlook Key Takeaways from the Hepatitis D Pipeline Report In June 2025, Ribocure Pharmaceuticals AB announced clinical trial is to learn if drug RBD1016 works to treat chronic hepatitis D virus infection in adults. It will also learn about the safety of drug RBD1016. There will be 2 treatment groups - an active group (n=10) and a deferred active group (n=5), with participants allocated randomly. In the active group, participants will receive RBD1016. In the deferred active group, participants will receive 4 doses of placebo followed by deferred treatment with doses of RBD1016. In June 2025, Vir Biotechnology Inc. conducted Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment. DelveInsight's Hepatitis D Pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Hepatitis D treatment. The leading Hepatitis D Companies such as Vir Biotechnology, Inc./Alnylam Pharmaceuticals, Bluejay Therapeutics, Inc., Ribocure Pharmaceuticals AB, Assembly Biosciences, Shanghai HEP Pharmaceutical Co., Ltd., Huahui Health and others. Promising Hepatitis D Pipeline Therapies such as Brelovitug 300 mg, lonafarnib, Ritonavir, Bulevirtide, Peginterferon Alfa-2a (PEG-IFN alfa), hepalatide, Peginterferon Lambda-1a and others. Stay ahead with the most recent pipeline outlook for Hepatitis D. Get insights into clinical trials, emerging therapies, and leading companies with Hepatitis D @ Hepatitis D Treatment Drugs Hepatitis D Emerging Drugs Profile Tobevibart + Elebsiran: Vir Biotechnology/ Alnylam Pharmaceuticals Tobevibart is an investigational broadly neutralizing monoclonal antibody targeting the hepatitis B surface antigen. It is designed to inhibit the entry of hepatitis B and hepatitis delta viruses into hepatocytes, and to reduce the level of circulating viral and subviral particles in the blood. Tobevibart, which incorporates Xencor's Xtend™ and other Fc technologies, has been engineered to have an extended half-life and was identified using Vir Biotechnology's proprietary monoclonal antibody discovery platform. Elebsiran is an investigational hepatitis B virus-targeting small interfering ribonucleic acid (siRNA) designed to degrade hepatitis B virus RNA transcripts and limit the production of hepatitis B surface antigen. Current data indicates that it has the potential to have direct antiviral activity against hepatitis B virus and hepatitis delta virus. It is the first asset in Vir Biotechnology's collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical studies. Currently, this combination drug product is in Phase III stage of its development for the treatment of Hepatitis D. Brelovitug: Bluejay Therapeutics Brelovitug is an investigational, highly potent, pan-genotypic, fully human IgG1 mAb that targets the anti-HBsAg on both the HDV and the HBV. Brelovitug is designed to neutralize and remove hepatitis B and hepatitis D virions and deplete HBsAg-containing subviral particles, which gives brelovitug a potentially advantageous safety profile and makes it a potentially efficacious treatment for CHD, a condition with urgent unmet medical need. In addition, brelovitug has shown immunomodulatory functions in CHB patients, which may help to reconstitute antiviral immunity and contribute to functional cure for CHB when combined with other agents. Currently, the drug is in the Phase II/III stage of its development for the treatment of Hepatitis D. RBD1016: Ribocure Pharmaceuticals AB RBD1016 is a GalNAc-siRNA drug independently developed by Ribo based on its proprietary GalNAc-siRNA platform, targeting the X gene of hepatitis B virus. It inhibits all four HBV transcripts through the RNA interference mechanism, and can simultaneously inhibit HBV DNA replication, reduce cccDNA and integrate DNA derived HBsAg and other antigens. RBD1016 demonstrates well-tolerated safety profile in Phase I study including both healthy subjects and patients with CHB infection. RBD1016 shows a highly efficient long-acting effect of reducing the HBsAg in patients. Currently, the drug is in Phase II stage of its development for the treatment of Hepatitis D. The Hepatitis D Pipeline Report Provides Insights into- The report provides detailed insights about companies that are developing therapies for the treatment of Hepatitis D with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hepatitis D Treatment. Hepatitis D Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Hepatitis D Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hepatitis D market Explore groundbreaking therapies and clinical trials in the Hepatitis D Pipeline. Access DelveInsight's detailed report now! @ New Hepatitis D Drugs Hepatitis D Companies Vir Biotechnology, Inc./Alnylam Pharmaceuticals, Bluejay Therapeutics, Inc., Ribocure Pharmaceuticals AB, Assembly Biosciences, Shanghai HEP Pharmaceutical Co., Ltd., Huahui Health and others. Hepatitis D pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Hepatitis D Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of Hepatitis D Treatment. Learn about new drugs, Hepatitis D Pipeline developments, and key companies with DelveInsight's expert analysis @ Hepatitis D Market Drivers and Barriers Scope of the Hepatitis D Pipeline Report Coverage- Global Hepatitis D Companies- Vir Biotechnology, Inc./Alnylam Pharmaceuticals, Bluejay Therapeutics, Inc., Ribocure Pharmaceuticals AB, Assembly Biosciences, Shanghai HEP Pharmaceutical Co., Ltd., Huahui Health and others. Hepatitis D Pipeline Therapies- Brelovitug 300 mg, lonafarnib, Ritonavir, Bulevirtide, Peginterferon Alfa-2a (PEG-IFN alfa), hepalatide, Peginterferon Lambda-1a and others. Hepatitis D Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Hepatitis D Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Hepatitis D Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Hepatitis D Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Hepatitis D: Overview Pipeline Therapeutics Therapeutic Assessment Hepatitis D– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Tobevibart + Elebsiran: Vir Biotechnology/ Alnylam Pharmaceuticals Drug profiles in the detailed report….. Mid Stage Products (Phase II/III) Brelovitug: Bluejay Therapeutics Drug profiles in the detailed report….. Early Stage Products (Phase I) Drug Name: Company Name Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products Hepatitis D Key Companies Hepatitis D Key Products Hepatitis D- Unmet Needs Hepatitis D- Market Drivers and Barriers Hepatitis D- Future Perspectives and Conclusion Hepatitis D Analyst Views Hepatitis D Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:

B-cell Non-hodgkin Lymphoma Clinical Trials, Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis
B-cell Non-hodgkin Lymphoma Clinical Trials, Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis

Globe and Mail

time8 hours ago

  • Globe and Mail

B-cell Non-hodgkin Lymphoma Clinical Trials, Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis

"B-cell Non-hodgkin Lymphoma Pipeline Insights" DelveInsight's, 'B-Cell Non-Hodgkin Lymphoma - Pipeline Insight, 2025' report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in B-Cell Non-Hodgkin Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. According to DelveInsight, over 75 major companies are actively engaged in the development of more than 80 treatment therapies for B-cell non-Hodgkin lymphoma. B-cell Non-hodgkin Lymphoma Overview: B-cell non-Hodgkin lymphoma (NHL) is a type of cancer that arises from abnormal B lymphocytes—white blood cells essential to the immune system. It accounts for over 85% of all NHL cases, making it the most common subtype. B-cell NHL includes several subtypes, classified based on cell morphology, surface proteins, and genetic traits. Key subtypes include diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and Burkitt lymphoma. The disease typically starts in the lymph nodes or lymphoid tissues and can spread to other organs, such as the gastrointestinal tract. Common symptoms include painless swollen lymph nodes, fever, night sweats, fatigue, weight loss, itchy skin, and pain in the chest, abdomen, or bones. When fever, night sweats, and weight loss occur together, they are known as B symptoms and are important for staging and prognosis. Diagnosing B-cell NHL—especially types with small- to medium-sized cells—can be difficult due to their resemblance to reactive lymphadenopathy and other lymphomas. Accurate diagnosis relies on a combination of techniques, including immunohistochemistry and flow cytometry, which must be interpreted in the context of the patient's clinical presentation and cellular morphology. Proper recognition of cytologic features is key to choosing the right diagnostic tests. Subtypes such as marginal zone lymphoma, follicular lymphoma, mantle cell lymphoma, CLL/SLL, and lymphoplasmacytic lymphoma are often misdiagnosed based on cytology alone. Therefore, a lymph node biopsy is usually necessary for definitive diagnosis and proper classification. "B-cell Non-hodgkin Lymphoma Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the B-cell Non-hodgkin Lymphoma Therapeutics Market. Key Takeaways from the B-cell Non-hodgkin Lymphoma Pipeline Report DelveInsight's B-cell Non-hodgkin Lymphoma pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for B-cell Non-hodgkin Lymphoma treatment. In May 2023, Bristol Myers Squibb announced positive topline results from two studies: TRANSCEND FL, a global, multicenter Phase 2 study evaluating Breyanzi (lisocabtagene maraleucel) in patients with relapsed or refractory follicular lymphoma (FL), and TRANSCEND NHL 001, a pivotal Phase 1 study assessing Breyanzi in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL), including mantle cell lymphoma (MCL). Both studies met the primary endpoint of overall response rate, with Breyanzi showing statistically significant and clinically meaningful responses in relapsed or refractory FL and MCL. In May 2023, Janssen Biotech, a subsidiary of Johnson & Johnson, announced a global collaboration and licensing agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture, and commercialize next-generation CAR T-cell therapies for treating B-cell malignancies. In May 2023, Genmab A/S revealed that the FDA approved EPKINLY™ (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from indolent lymphoma, after two or more lines of systemic therapy. In January 2023, Fate Therapeutics, Inc. announced it had declined a proposal from Janssen Biotech to continue their collaboration and option agreement under revised terms, leading to the termination of the agreement and the winding down of all collaboration activities in the first quarter of 2023. Key B-cell Non-hodgkin Lymphoma companies such as Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy, Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics, and others are evaluating new drugs for B-cell Non-hodgkin Lymphoma to improve the treatment landscape. Promising B-cell Non-hodgkin Lymphoma pipeline therapies in various stages of development include Valemetostat, MB-106, CB-010, LP-284, and others. B-cell Non-hodgkin Lymphoma Pipeline Analysis The report provides insights into: The report provides detailed insights into the key companies that are developing therapies in the B-cell Non-hodgkin Lymphoma Market. The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for B-cell Non-hodgkin Lymphoma treatment. It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the B-cell Non-hodgkin Lymphoma market. Download our free sample page report on B-cell Non-hodgkin Lymphoma pipeline insights B-cell Non-hodgkin Lymphoma Emerging Drugs Valemetostat: Daiichi Sankyo MB-106: Mustang Bio CB-010: Caribou Biosciences LP-284: Lantern Pharma B-cell Non-hodgkin Lymphoma Companies Over 75 key companies are working on developing therapies for B-cell non-Hodgkin lymphoma. Among them, Daiichi Sankyo has drug candidates for B-cell non-Hodgkin lymphoma in the advanced Phase II stage. DelveInsight's report covers around 22+ products under different phases of clinical development like Late stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) along with the details of Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates B-cell Non-hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intravenous Subcutaneous Oral Intramuscular B-cell Non-hodgkin Lymphoma Products have been categorized under various Molecule types such as Monoclonal antibody Small molecule Peptide Download Sample Pages to Get an in-depth Assessment of the Emerging B-cell Non-hodgkin Lymphoma Therapies and Key Companies: B-cell Non-hodgkin Lymphoma Clinical Trials and advancements B-cell Non-hodgkin Lymphoma Pipeline Therapeutic Assessment • B-cell Non-hodgkin Lymphoma Assessment by Product Type • B-cell Non-hodgkin Lymphoma By Stage • B-cell Non-hodgkin Lymphoma Assessment by Route of Administration • B-cell Non-hodgkin Lymphoma Assessment by Molecule Type Download B-cell Non-hodgkin Lymphoma Sample report to know in detail about the B-cell Non-hodgkin Lymphoma treatment market @ B-cell Non-hodgkin Lymphoma Therapeutic Assessment Table of Content 1. Report Introduction 2. Executive Summary 3. B-cell Non-hodgkin Lymphoma Current Treatment Patterns 4. B-cell Non-hodgkin Lymphoma - DelveInsight's Analytical Perspective 5. Therapeutic Assessment 6. B-cell Non-hodgkin Lymphoma Late-Stage Products (Phase-III) 7. B-cell Non-hodgkin Lymphoma Mid-Stage Products (Phase-II) 8. Early Stage Products (Phase-I) 9. Pre-clinical Products and Discovery Stage Products 10. Inactive Products 11. Dormant Products 12. B-cell Non-hodgkin Lymphoma Discontinued Products 13. B-cell Non-hodgkin Lymphoma Product Profiles 14. B-cell Non-hodgkin Lymphoma Key Companies 15. B-cell Non-hodgkin Lymphoma Key Products 16. Dormant and Discontinued Products 17. B-cell Non-hodgkin Lymphoma Unmet Needs 18. B-cell Non-hodgkin Lymphoma Future Perspectives 19. B-cell Non-hodgkin Lymphoma Analyst Review 20. Appendix 21. Report Methodology Request the Sample PDF to Get Detailed Insights About the B-cell Non-hodgkin Lymphoma Pipeline Reports Offerings Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Kritika Rehani Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store